bladder cancer

The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
Neoadjuvant gemcitabine-based chemotherapy, followed by gemcitabine-based concomitant chemoradiation, may aid in bladder preservation for patients receiving treatment for muscle-invasive bladder cancer in under-resourced countries.
Few patients with metastatic urothelial carcinoma of the bladder are surviving as long in the real-world as those in clinical trials, according to new research.
Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma is often foregone in community cancer centers and academic centers.
An anti-PD-1 therapy significantly improves overall survival compared with chemotherapy in previously treated patients with advanced bladder cancer, according to a study presented at the Society for Immunotherapy of Cancer 2016 meeting.
The neutrophil-to-lymphocyte ratio may not be as reliable as previously believed at predicating cancer progression and which drugs will be the most effective.